Evidence map›Paper›PMID 38654107›Full record

ArticleOncogene2024

ZBTB16 inhibits DNA replication and induces cell cycle arrest by targeting WDHD1 transcription in lung adenocarcinoma.

Kai Wang, Deyu Guo, Tao Yan, Shijie Sun, Yadong Wang, Haotian Zheng, Guanghui Wang, Jiajun Du

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Kai Wang *Institute of Oncology, Shandong Provincial Hospital, Shandong University, Jinan, China.
Deyu Guo *Institute of Oncology, Shandong Provincial Hospital, Shandong University, Jinan, China.
Tao YanLung Transplantation Center, Department of Thoracic Surgery, Nanjing Medical University Affiliated Wuxi People's Hospital, Wuxi, China.
Shijie SunInstitute of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Yadong WangInstitute of Oncology, Shandong Provincial Hospital, Shandong University, Jinan, China.ORCID 0000-0002-3741-9740
Haotian ZhengInstitute of Oncology, Shandong Provincial Hospital, Shandong University, Jinan, China.
Guanghui WangInstitute of Oncology, Shandong Provincial Hospital, Shandong University, Jinan, China.
Jiajun DuInstitute of Oncology, Shandong Provincial Hospital, Shandong University, Jinan, China. dujiajun@sdu.edu.cn.ORCID 0000-0003-2406-9435
Shandong University · CNShandong Provincial Hospital · CNWuxi People's Hospital · CN

Funding

Natural Science Foundation of Shandong Province (Shandong Provincial Natural Science Foundation) ZR2021MH192
6 · The paper itself

Abstract

Lung adenocarcinoma is a malignant tumor with high morbidity and mortality. ZBTB16 plays a double role in various tumors; however, the potential mechanism of ZBTB16 in the pathophysiology of lung adenocarcinoma has yet to be elucidated. We herein observed a decreased expression of ZBTB16 mRNA and protein in lung adenocarcinoma and a significantly increased DNA methylation level of ZBTB16 in patients with lung adenocarcinoma. Analysis of public databases and patients' clinical data indicated a close association between ZBTB16 and patient survival. Ectopic expression of ZBTB16 in lung adenocarcinoma cells significantly inhibited cell proliferation, invasion, and migration. It also induced cell cycle arrest in the S phase. Meanwhile, mitotic catastrophe was induced, and DNA damage and apoptosis occurred. In line with these findings, the overexpression of ZBTB16 in xenograft mice resulted in the inhibition of tumor growth. Comprehensive analysis showed that WDHD1 was a potential target for ZBTB16. The overexpression of both isoforms of WDHD1 significantly reversed the ZBTB16-mediated inhibition of lung adenocarcinoma proliferation and cell cycle. These studies suggest that ZBTB16 impedes the progression of lung adenocarcinoma by interfering with WDHD1 transcription, making it a potential novel therapeutic target in the management of lung adenocarcinoma.

Indexed as

Adenocarcinoma of LungCell Cycle CheckpointsCell ProliferationDNA ReplicationLung NeoplasmsAnimalsApoptosisCell Line, TumorCell MovementDNA-Binding ProteinsDNA MethylationFemaleGene Expression Regulation, NeoplasticHumansMaleMiceDNA-Binding ProteinsPromyelocytic Leukemia Zinc Finger ProteinWDHD1 protein, humanZBTB16 protein, human

Identifiers

PMID38654107
OpenAlexW4395048192

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.